The National Academies

The National Academies: What You Need To Know About Infectious Disease

What You Need To Know About Infectious Disease

Globalization, Biosecurity, and the Future of the Life Sciences (2006)

Biomedical advances have made it possible to identify and manipulate features of living organisms in useful ways, leading to improvements in public health, agriculture, and other areas. The globalization of scientific and technical expertise also means that many scientists and other individuals around the world are generating breakthroughs in the life sciences and related technologies. The risks posed by bioterrorism and the proliferation of biological weapons capabilities have increased concern about how the rapid advances in genetic engineering and biotechnology could enable the production of biological weapons with unique and unpredictable characteristics. Globalization, Biosecurity, and the Future of Life Sciences examines current trends and future objectives of research in public health, life sciences, and biomedical science that contain applications relevant to developments in biological weapons 5 to 10 years into the future and ways to anticipate, identify, and mitigate these dangers.

View This Source

Related Reports

Explore Other Topics

What do you know about infectious disease?

True or False: Major pharmaceutical companies have great interest in dedicating resources to the antibiotics market because these short-course drugs are more profitable than drugs that treat chronic conditions and lifestyle ailments, such as high blood pressure or high cholesterol.

  • Sorry, that’s incorrect.

    Drugs that treat chronic conditions and lifestyle ailments are more profitable. Modern medicine needs new kinds of antibiotics to treat drug-resistant infections, but antibiotic research and development are expensive, risky, and time-consuming.

  • Correct!

    Drugs that treat chronic conditions and lifestyle ailments are more profitable. Modern medicine needs new kinds of antibiotics to treat drug-resistant infections, but antibiotic research and development are expensive, risky, and time-consuming.